Pfizer, BioNTech to supply 200 million doses of Covid-19 vaccine to Europe
Pfizer and BioNTech are expected to begin the delivery of BNT162b2 vaccine by the end of 2020, pursuant…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
12 Nov 20
Pfizer and BioNTech are expected to begin the delivery of BNT162b2 vaccine by the end of 2020, pursuant…
12 Nov 20
The efficacy of the Sputnik V vaccine is calculated based on 20 confirmed Covid-19 cases, who received either…
11 Nov 20
Treatment using tezepelumab in the NAVIGATOR Phase 3 clinical trial was well tolerated in patients with severe asthma
10 Nov 20
The vaccine candidate was more than 90% effective in preventing Covid-19 in participants without prior SARS-CoV-2 infection
10 Nov 20
NVX-CoV2373 is being studied under Phase 3 clinical trial in the UK, with additional trials planned in the…
09 Nov 20
The acquisition will help Novo Nordisk expand its portfolio of oral biologic pipeline assets by using Emisphere’s drug…
06 Nov 20
The acquisition will strengthen Merck’s oncology portfolio with investigational antibody-drug conjugate VLS-101 for blood cancers and solid tumours
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Nov 20
The maintenance treatment using the drug regimen reduced the risk of disease progression or death by 67%, and…
05 Nov 20
Novavax will supply NVX-CoV2373 to Australia from the first half of 2021, subject to Phase 3 clinical trials…
05 Nov 20
The partnership will develop advanced analytical solutions and deliver training to address the current requirements of the biopharmaceutical…
PharmaceuticalsConsulting, Training and Other Pharmaceutical Services